SOLANA BEACH, Calif. and REDWOOD CITY, Calif., June 24, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) today announced that the Company has terminated its employees and will wind down it operations, including seeking potential strategic alternatives for the Company’s development programs. This decision was made at a special meeting of the board of directors. Further, as previously disclosed, the... Read More

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced a collaboration to conduct an investigator-sponsored trial (IST) evaluating zotatifin in combination with abemaciclib and letrozole in patients with estrogen receptor-positive... Read More

Dose escalation of zotatifin in the ZFA triplet ongoing at 0.14 mg/kg, with RP2D expected in H2 2024 Raised $15.0 million in gross proceeds from registered direct financing, extending cash runway into first quarter of 2025 SOLANA BEACH, Calif. and REDWOOD CITY, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs)... Read More

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced that the Company will present at the Stifel Virtual Oncology Forum on Tuesday, April 16 th at 11:30 am ET. A live webcast of the virtual presentation will be available on... Read More

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced topline results from the primary analysis of the randomized Phase 2 KICKSTART trial which tested tomivosertib or placebo, each combined with pembrolizumab, as frontline... Read More

Topline data from the randomized Phase 2b KICKSTART trial of tomivosertib combined with pembrolizumab in non-small cell lung cancer (NSCLC) expected in early April 2024 Median progression free survival (mPFS) of 7.4 months in the ZFA expansion cohort evaluating zotatifin in combination with fulvestrant and abemaciclib in heavily pretreated patients Received U.S. FDA Fast Track designation for zotatifin in combination with... Read More

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced that Steve Worland, Ph.D., president, and chief executive officer of eFFECTOR, will present at the Oppenheimer 34 th Annual Healthcare Life Sciences Conference on Wednesday,... Read More

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) (the “Company”), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced that it has closed its previously announced registered direct offering with a new healthcare focused institutional investor for the purchase and sale of an... Read More

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) (the “Company”), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced that it has entered into a definitive agreement with a single healthcare focused institutional investor for the purchase and sale of an aggregate of 1,488,834... Read More

Summary of development progress for tomivosertib and zotatifin and a preview of anticipated 2024 milestones Review of recently announced interim data from dose escalation and Phase 2 expansion cohorts of zotatifin in ER+ metastatic breast cancer patients Webinar to take place on Wednesday, January 24, 2024, at 4:30 pm ET SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Jan. 09, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics,... Read More

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Jan. 09, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced that its Board of Directors (the “Board”) has approved a 1-for-25 reverse stock split of the Company’s common stock. The reverse stock split will become effective at 12:01... Read More

Median progression free survival (mPFS) of 7.4 months in the ZFA expansion cohort evaluating zotatifin in combination with fulvestrant and abemaciclib in heavily pretreated patients Zotatifin generally well tolerated as dose escalation continues; Currently enrolling at 0.28 mg/kg in the ZF doublet evaluating zotatifin combined with fulvestrant and at 0.1 mg/kg in the ZFA triplet SOLANA BEACH, Calif. and REDWOOD CITY, Calif.,... Read More

Designation is for 2 nd or 3 rd line treatment of patients with disease progression following treatment with endocrine therapy and a CDK 4/6 inhibitor Data updates and further development plans to be presented at 2023 San Antonio Breast Cancer Symposium (SABCS) SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective... Read More

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Nov. 15, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced a poster presentation of new clinical data from dose escalation and Phase 2 expansion cohorts of a Phase 1/2 clinical study of zotatifin in patients with estrogen receptor... Read More

Management intends to provide an update on its zotatifin clinical development program in estrogen receptor-positive (ER+) metastatic breast cancer (mBC) at the 2023 San Antonio Breast Cancer Symposium (SABCS) Topline results from Phase 2b KICKSTART trial in non-small cell lung cancer (NSCLC) now anticipated in first quarter of 2024 Collaboration initiated with Northwestern University on investigator-initiated Phase 1 dose... Read More

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced that the Company will participate in a fireside chat discussion and host 1x1 meetings at the 2023 Stifel Healthcare Conference taking place November 14-15, 2023 in New York,... Read More

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Oct. 24, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced the initiation of dosing in an investigator-initiated Phase 1 dose escalation trial evaluating tomivosertib in patients with relapsed/refractory Acute Myeloid Leukemia (AML).... Read More

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced the addition of Caroline Loewy to its Board of Directors and her election as Chair of the Board’s Audit Committee. Concurrent with Ms. Loewy’s appointment, current Board... Read More

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced that the management team will participate in and host 1x1 meetings at the following upcoming investor conferences: Presentation at the H.C. Wainwright 25th Annual Global... Read More

Positive data update from Phase 2 expansion cohort evaluating zotatifin combined with fulvestrant and abemaciclib (ZFA triplet) in estrogen receptor-positive (ER+) metastatic breast cancer (mBC) presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023 Continued progress in dose-escalation study with zotatifin in combination with fulvestrant in ER+ mBC, with data anticipated in the second half of 2023... Read More

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, announced today that it has closed its previously announced $8.7 million registered direct offering for the purchase and sale of an aggregate of 7,764,445 shares of its common stock (or common... Read More

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the purchase and sale of an aggregate of 7,764,445 shares of its... Read More

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, announced today that it has closed its previously announced registered direct offering for the purchase and sale of an aggregate of 11,450,382 shares of its common stock (or common stock... Read More

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., May 26, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the purchase and sale of an aggregate of 11,450,382 shares of its... Read More

Partial responses observed in 5 of 19 (26%) evaluable patients treated with zotatifin 0.07 mg/kg combined with fulvestrant and abemaciclib (ZFA triplet) in heavily pretreated population Partial response observed in 1 of 3 (33%) patients treated with zotatifin 0.1 mg/kg combined with fulvestrant (ZF doublet) Both combinations were generally well tolerated with large majority of adverse events Grade 1 or 2 Company will host a... Read More

Updated data from two fully enrolled Phase 2 expansion cohorts testing zotatifin-based combinations in estrogen receptor-positive (ER+) Metastatic Breast Cancer to be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023 on June 4, 2023 Company will host conference call to discuss results and further development of zotatifin during ASCO Annual Meeting 2023 Zotatifin is being evaluated in patients... Read More

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced that the Company will present and host 1x1 meetings at the JMP Securities Life Sciences Conference taking place May 15-16, 2023 in New York, NY. Steve Worland, Ph.D.,... Read More

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced a poster highlighting results from Phase 2 expansion cohorts of a Phase 1/2 dose escalation and expansion trial with zotatifin in patients with ER+ Metastatic Breast Cancer... Read More

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., April 11, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced a clinical collaboration with Jennifer Caswell-Jin, M.D., Assistant Professor of Medicine at Stanford Medicine, who will serve as principal investigator in an... Read More

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced that the management team will participate in and host 1x1 meetings at the following upcoming investor conferences: Fireside Chat at Cantor’s the Future of Oncology Virtual... Read More

Zotatifin continued to demonstrate favorable activity and tolerability, including two previously reported confirmed partial responses (PRs) among seven heavily pretreated subjects who received zotatifin, fulvestrant and abemaciclib (ECBF+A) Enrollment in expanded ECBF+A cohort completed and data is anticipated in first half of 2023 Topline data for Phase 2b KICKSTART trial in NSCLC anticipated in second half of 2023 Cash... Read More

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Feb. 21, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced top-line results from its Phase 1b clinical trial of zotatifin for the treatment of COVID demonstrating favorable safety results as well as positive trends in several measures... Read More

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Jan. 30, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, announced that the Company will present and host 1x1 meetings at the 2023 BIO CEO & Investor Conference from February 6-9, 2023 in New York City, NY. Steve Worland, Ph.D., president and... Read More

Zotatifin continues to show favorable activity profile, including two confirmed partial responses (PR) among seven heavily pretreated subjects who received zotatifin, fulvestrant and abemaciclib (ECBF+A), with good tolerability eFFECTOR to focus on front-line PD-L1 ≥ 50% cohort of KICKSTART trial with tomivosertib in non-small cell lung cancer Management to present results and provide full pipeline update in investor call on... Read More

eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced that the management team will participate in and host 1x1 meetings at the following upcoming investor conferences: Fireside Chat at Credit Suisse 31st Annual Healthcare Conference on November 8th at 2pm PT Fireside Chat at Stifel 2022 Healthcare... Read More

eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced it has completed enrollment for the second cohort of a three cohort Phase 1b clinical trial of zotatifin in non-hospitalized adults with confirmed COVID-19 infection. eFFECTOR anticipates opening enrollment in the third cohort by the end of 2022, and... Read More

eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced it has appointed Mayank J. Gandhi, M.D., as chief business officer. Dr. Gandhi will lead eFFECTOR’s corporate growth strategy, business development and partnership opportunities. “Mayank is an accomplished leader with extensive experience in the... Read More

eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced that the Company will participate in a panel discussion and host 1x1 meetings at the upcoming Cantor Oncology, Hematology, HemeOnc Conference. Panel Topic: “Building Combinations: What are the Novel Ideas?” Date: Wednesday, September 28, 2022 Time: 10:40... Read More

Dose escalation based on positive recommendation from independent data safety monitoring board after safety review of cohort 1 Drug levels achieved with sub-cutaneous formulation equivalent to IV formulation eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced it has dosed the first patient in the second... Read More

eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced that the Company will present and host 1x1 meetings at the upcoming H.C. Wainwright 24 th Annual Global Investment Conference . Presentation Date: Monday, September 12, 2022 Time: 9:30 AM ET Presenter: Steve Worland, Ph.D., President and Chief Executive... Read More

Presented positive interim results at ASCO 2022 from ongoing zotatifin Phase 1/2 dose escalation and expansion trial Appointed Doug Warner, M.D., as chief medical officer eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today reported financial results for the second quarter ended June 30, 2022, and provided a corporate... Read More

eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced it has appointed Douglas Warner, M.D., as chief medical officer. Dr. Warner will develop strategies to continue advancing eFFECTOR’s two clinical-stage STRIs into advanced and potentially registrational trials. “Dr. Warner has extensive experience in... Read More

eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a biopharmaceutical company pioneering the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced that the Company will present and host 1x1 meetings at JMP Securities Life Sciences Conference. The eFFECTOR Team is scheduled to hold a fireside chat on June 15th at 10:30 am ET and will host investor meeting at the conference... Read More

Two partial responses observed in heavily pre-treated ER+ breast cancer patients One ongoing cohort in ER+ breast cancer has been expanded and new expansion cohort planned in ER+ breast cancer patients with Cyclin D amplification Management and key opinion leaders to present results and provide update on expanded development of zotatifin in investor call on June 5th at 7 p.m. ET / 6 p.m. CT eFFECTOR Therapeutics, Inc.... Read More

Positive initial data demonstrated pharmacologically relevant exposures Management and key opinion leaders to present complete results and provide update on expanded development of zotatifin in investor call on June 5 th at 7 p.m. ET / 6 p.m. CT eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced that it... Read More

Plan to present data at ASCO 2022 from ongoing zotatifin Phase 1/2 dose escalation and expansion trial Intend to provide an update on expanded development of zotatifin eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today reported financial results for the first quarter ended March 31, 2022, and provided a corporate... Read More

eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a biopharmaceutical company pioneering the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced that the management team will participate in and host 1x1 meetings at the following upcoming investor conferences: Fireside Chat at 2022 RBC Capital Markets Global Healthcare Conference on Wednesday, May 18 th at 1:35 pm EDT... Read More

Premal Patel, M.D., Ph.D., chief medical officer, has resigned to pursue a new career opportunity Robert Sikorski, M.D., Ph.D., to take on expanded role as senior clinical development advisor eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a biopharmaceutical company pioneering the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced that its chief medical officer Premal... Read More

eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today reported financial results for the fourth quarter and year ended December 31, 2021, and provided a corporate update. “2021 was a momentous year for eFFECTOR, as we advanced both our clinical stage assets, tomivosertib and zotatifin, into Phase 2 trials and raised... Read More

eFFECTOR Therapeutics (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced the appointment of Kristen Harrington-Smith, Senior Vice President & Chief Commercial Officer at ImmunoGen, to the company’s board of directors. Concurrent with Ms. Harrington-Smith’s appointment, Jonathan Root, M.D., has resigned from the company’s board of... Read More

eFFECTOR Therapeutics (NASDAQ: EFTR), a biopharmaceutical company focused on pioneering the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced that the Company will present and host 1x1 meetings at the 2022 BIO CEO & Investor Conference. Steve Worland, Ph.D., President and Chief Executive Officer of eFFECTOR, will provide an overview of the Company’s clinical... Read More

Tomivosertib development strategy updated, including addition of a new cohort in Phase 2b KICKSTART trial in non-small cell lung cancer (NSCLC) evaluating frontline maintenance in PD-L1 ≥1% patient population, representing additional $5 billion U.S. market opportunity First patients dosed in two additional Phase 2 expansion cohorts evaluating zotatifin in combination with sotorasib in KRAS G12C-mutant NSCLC and in... Read More

eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, announced today the publication of data highlighting the anti-tumor potential of zotatifin, the company’s clinical-stage inhibitor of eukaryotic translation initiation factor 4A (“eIF4A”), in the peer-reviewed journal Frontiers in Oncology . eIF4A is a catalytic component... Read More

eFFECTOR Therapeutics (NASDAQ: EFTR), a biopharmaceutical company focused on pioneering the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced that Steve Worland, Ph.D., President and Chief Executive Officer of eFFECTOR, will participate in a fireside chat at the JMP Securities Hematology and Oncology Summit on Monday, December 6 at 3:20 p.m. ET. A live webcast of... Read More

• Continuing to enroll patients in Phase 2b KICKSTART study of tomivosertib in combination with pembrolizumab, a U.S. Food and Drug Administration (FDA) approved PD-1 inhibitor • Selected recommended Phase 2 dose (RP2D) of zotatifin for continued development for patients with certain solid tumors • Commenced enrollment in Phase 2a indication-specific expansion cohorts of zotatifin study • Debuted as publicly-traded... Read More

eFFECTOR Therapeutics (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced the appointment of Barbara Klencke, M.D., Chief Medical Officer and Chief Development Officer at Sierra Oncology, to the company’s board of directors. Concurrent with Dr. Klencke’s appointment, Larry Lasky, Ph.D., has resigned from the company’s board of... Read More

eFFECTOR Therapeutics (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced that management will participate in and host 1x1 meetings at the following upcoming investor conferences: Presentation at Credit Suisse 30th Annual Virtual Healthcare Conference on Monday, November 8 th at 12:10 PM EST Fireside Chat at Stifel 2021 Virtual... Read More

Demonstrated statistically significant anti-tumor activity and inhibited proliferative and stem-cell signaling pathways Induced beneficial changes in the tumor microenvironment by increasing production of proteins involved in interferon- α and interferon- γ pathways Demonstrated statistically significant increases in survival when combined with carboplatin and everolimus (mTOR inhibitor) eFFECTOR Therapeutics (NASDAQ: EFTR),... Read More

eFFECTOR Therapeutics (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced that eFFECTOR-supported research from Baylor College of Medicine entitled, “ The RNA helicase EIF4A is a therapeutic vulnerability in triple-negative breast cancer” has been accepted as a poster presentation at the upcoming 2021 AACR-NCI-EORTC International... Read More

eFFECTOR Therapeutics (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced that company management will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference at 2:40 p.m. ET on Tuesday, September 28, 2021. eFFECTOR will also host investor meetings throughout the conference. A live webcast of the fireside... Read More